These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38557171)

  • 21. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
    Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The addition of avibactam renders piperacillin an effective treatment for
    Meir M; Bifani P; Barkan D
    Antimicrob Resist Infect Control; 2018; 7():151. PubMed ID: 30564307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam.
    Bonnin RA; Bernabeu S; Emeraud C; Creton E; Vanparis O; Naas T; Jousset AB; Dortet L
    Int J Antimicrob Agents; 2022 Oct; 60(4):106660. PubMed ID: 35988666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
    Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
    J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes.
    Nguyen DC; Dousa KM; Kurz SG; Brown ST; Drusano G; Holland SM; Kreiswirth BN; Boom WH; Daley CL; Bonomo RA
    Clin Infect Dis; 2021 Oct; 73(8):1532-1536. PubMed ID: 34113990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR Inhibition of Essential Peptidoglycan Biosynthesis Genes in Mycobacterium abscessus and Its Impact on β-Lactam Susceptibility.
    Kurepina N; Chen L; Composto K; Rifat D; Nuermberger EL; Kreiswirth BN
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0009322. PubMed ID: 35311518
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycobacterium abscessus l,d-Transpeptidases Are Susceptible to Inactivation by Carbapenems and Cephalosporins but Not Penicillins.
    Kumar P; Chauhan V; Silva JRA; Lameira J; d'Andrea FB; Li SG; Ginell SL; Freundlich JS; Alves CN; Bailey S; Cohen KA; Lamichhane G
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
    Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potency of Meropenem-Vaborbactam in Lung Surfactant.
    Rubio-Aparicio D; Loutit J; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex.
    Lavollay M; Dubée V; Heym B; Herrmann JL; Gaillard JL; Gutmann L; Arthur M; Mainardi JL
    Clin Microbiol Infect; 2014 May; 20(5):O297-300. PubMed ID: 24112243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
    Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the
    Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Cheng A; Tsai YT; Chang SY; Sun HY; Wu UI; Sheng WH; Chen YC; Chang SC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670428
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Le Run E; Arthur M; Mainardi JL
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.